The American Psychiatric Association and academic psychiatry in the United
Introduction
Cognitive dissonance theory provides a framework for understanding why financial and intellectual conflicts of interest can result in biased clinical decision-making and why transparency-the disclosure of such conflicts-does not provide an adequate remedy to the conflict. In short, cognitive dissonance studies reveal that individuals who have a financial conflict of interest, or are working within an institution that has come under the economic influence of an outside group, often cannot consciously see how the conflict may be compromising their behavior.
Seventy five years ago, Upton Sinclair summed up this ethical blind spot well: "It's difficult to get a man to understand something if his salary depends upon his not
The Hidden Mind
Cognitive dissonance theory grew out of research intent on understanding what people do when they are confronted with information that creates conflicted psychological states. Although Leon Festinger's original cognitive dissonance theory from 1957 has been revised multiple times, the basic premise remains that individuals experience cognitive dissonance when their behavior is at odds with their ethical beliefs, or when they are trying to hold incompatible thoughts.
2 Individuals experiencing cognitive dissonance have a desire to reduce their feelings of discomfort by attempting to reconcile their conflicting beliefs and behaviors, or their incompatible thoughts, especially if the dissonance is esteem-related (e.g., is related to how one sees oneself professionally). For instance, if a physician is a paid by a drug company to act as a consultant or speaker, that physician may need to remain convinced that he or she is still objective about the merits of the company's drugs, in spite of the financial payment.
As Harvard psychologist Mazahrin Banaji and colleagues have empirically demonstrated, a person is able to hold this self-protecting thought because implicit 1 Sinclair Lewis, I, Candidate for Governor: And How I Got Licked, (1935 , reprint University of California Press, 1994 ; as cited by Wikiquotes, http://en.wikiquote.org/wiki/Upton_Sinclair. Psychology (American Psychological Association, 1999) , 3-21. biases, which can arise from financial conflicts, operate largely on the unconscious mind. 3 Thus, in the case described above, the physician is able to consciously maintain a steadfast belief in his or her objectivity even while behaving in ways that, to the outside observer, reveal that he or she has been affected by the financial incentives. Individuals may consciously recognize their potential conflict of interest while remaining unaware of how their behavior has been affected by it. This is why even radical transparency of financial ties (e.g., receiving honoraria, speaking fees, grant funding) cannot solve the pernicious problem of how such conflicts of interest can influence decision-making at every stage in the research process, and in the development of diagnostic and clinical care guidelines.
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Individuals with commercial ties and guild interests do not perceive that they are acting in a compromised manner, and thus disclosure is not likely to change their behavior, since they see themselves as unaffected by those financial conflicts.
Indeed, implicit biases, such as "pro-industry habits of thought," are extremely difficult to correct even when individuals are aware of them. 4 Clinical practice guidelines (CPGs) exert an enormous influence on prescription practices. They are seen by the medical profession as more trustworthy than expert opinion, because they are an unbiased, empirically derived set of recommendation statements. They are also seen as useful because they typically contain a decision tree or algorithm to guide the busy clinician inundated with too much-and sometimes contradictory-information. Thus, CPGs are intended to enhance the practice of evidence-based medicine by streamlining healthcare delivery and improving the process and outcomes of patient care. Additionally, insurance companies rely heavily on guidelines when deciding which treatments they will pay for, and although there is no rule that CPGs must be used, they are seen as an integral part of evidence-based medicine. 
Pharma's Influence on Psychiatry
In recent years, there has been considerable societal attention paid to the fact that financial conflicts of interest in psychiatry are pervasive. Indeed, they reach into every corner of this medical discipline.
In 1980, when the American Psychiatric Association published the third edition of its diagnostic and statistical manual (DSM III), it adopted a "medical model" for classifying mental disorders, which was a change that, as Robert Spitzer, architect of the manual later admitted, "delighted" the pharmaceutical industry. insiders refer to these physicians as "thought leaders," or "key opinion leaders" (KOLs). This type of conflict of interest among academic psychiatrists became so common that in 1998, when the New England Journal of Medicine sought to find an "expert" to write a review of treatments for depression, it found it difficult to identify one who didn't have such ties.
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More recently, Propublica, an investigative journalism group that tracks payments from 15 pharmaceutical firms to doctors for public speaking, found that from 2009
to 2012, at least 10 psychiatrists earned more than $500,000 giving such talks (and for consulting services.) The top earner in the Propublica database was Nashville psychiatrist Jon Draud, medical director of psychiatric medicine at two
Tennessee hospitals, who received more than $1 million from the firms that have publicly disclosed such payments. This is a setting ripe for cognitive dissonance to settle deeply into the field: the conflicts of interest almost certainly will impact the decision making of the APA, academic psychiatrists, and prescribing psychiatrists, while these professionals, in their conscious minds, tell themselves they are free from such bias.
Studies of Cognitive Dissonance in Physicians
Physicians have a desire to see themselves as altruistic, guided in their actions by a desire to serve their patients' best interests. A number of investigators have studied how doctors, when they are receiving a payment or a gift from a pharmaceutical company, resolve the cognitive dissonance that may arise.
In a survey of obstetricians and gynecologists, Morgan and colleagues found that the majority thought it was ethical to accept free drug samples (92%), a free informational lunch (77%), or a well-paid consultancy (53%). They reasoned that the free sample would be helpful to patients in financial need (or provide added convenience), and only a third thought that their prescribing habits would be influenced by the free samples. However, they did worry about their peers; they were more likely to conclude that the "average doctor's prescribing would be influenced by acceptance of the items than their own." 16 Similarly, in a survey of residents at a university-based program, Steinman found that 61% thought that their prescribing patterns would not be influenced by the free gifts, yet thought only 16% of "other physicians" would be immune to such freebies. Moreover, with this self-image in mind, a majority of the residents found it "appropriate" to accept free lunches, dinner lectures, reprinted articles, pens, textbooks, and even to go on a free "social outing." The residents, Steinman concluded, "believe they are not influenced" by gifts from industry.
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The experts in a field, including key opinion leaders, may be even more certain of their "objectivity" while they have financial ties to industry. Choudhry surveyed 192
authors of 44 clinical practice guidelines endorsed by North American and
European societies on common adult diseases, and found that 87% had ties to a drug company. On average, they had financial associations (e.g., honoraria, consulting, research funding), with more than 10 companies. Nearly two-thirds of the authors (64%) served as speakers for drug companies, and 59% had relationships with the companies whose drugs were considered in the guideline they wrote. Yet, only 7% of the authors thought that their financial ties to pharmaceutical companies "influenced" their recommendations, and only a slightly higher number-19%-thought their co-authors were so influenced. In other words, more than 80% of the experts were confident that the very involved financial relationships of the members of their group with pharmaceutical companies did not influence the clinical practice guidelines they produced.
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Chimonas and colleagues, in a study of the thought processes that physicians employ to manage such "cognitive inconsistencies," found that they regularly the conflict of interest, they disagreed that industry relationships affected physician behavior, they denied responsibility for the problem, they enumerated techniques for remaining impartial, and they reasoned that meetings with detailers were educational and benefited patients" Chimonas wrote. 19 The physicians' methods for resolving the conflict may have varied, but typically the end thought was the same: It was okay to accept free gifts because they would remain objective, even though others might be biased by such conflicts.
This self-image of physicians, noted former APA President Paul Appelbaum, is so strong that for many doctors even "the suggestion that they may be influenced by contact with the pharmaceutical or device industries is infuriating." As physicians receive money and gifts from pharmaceutical companies, they need to see themselves as remaining objective, acting in the best interests of their patients, and it is an affront to suggest otherwise. 
Under the Influence of Guild Interests
Scholars studying conflicts of interest within medicine usually focus on the influence of pharmaceutical money on academic physicians and the rest of the profession. Less attention is paid to guild interests, even though this influence may be more profound than financial payments from pharmaceutical companies.
In 1980, after the APA adopted a "medical model" for classifying mental disorders, the field was left with three main "products": research, the classification of mental disorders, and the prescribing of psychiatric drugs. Thus, the APA, as an organization, was taken off course by a growing dependency on drug firms and by internal interests (e.g., guild interests) and external influences (e.g., third party reimbursement practices incentivizing psychiatrists to act as psychopharmacologists rather than talk therapists). These factors led psychiatrists in the U.S. to effectively cede psychotherapy to to other mental health professionals, such as psychologists and social workers. Given these guild interests and external pressures (e.g. market pressures, insurance and managed care practices), it is easy to understand the tendency to dismiss certain research results. Research results that raise questions about the efficacy or safety of a class of drugs or findings from naturalistic studies that unmedicated patients did better over the long term, would provoke cognitive dissonance within the field. The APA as an organization, as well as leaders within the field, would be motivated to dismiss those results, or critique them in a way that would protect their own as well as a societal belief in the medications.
Moreover, this guild influence is likely going to be more hidden to the conscious mind than the influence due to a payment from a drug company. In the latter instance, there is a general societal understanding that such a situation does present a conflict of interest, which can lead to bias, and thus there is some conscious awareness that such payments may be a problem. But society is less aware that a guild interest may lead to biased judgment, and that is true of physicians too. Physicians' professional identity is predicated on the assumption that their treatment choices are evidence-based, and thus psychiatrists are not going to think that they may be motivated by a guild interest to protect societal belief in psychiatric medications.
Cognitive Dissonance Within Psychiatry
It is easy to see instances of cognitive dissonance at work in the public responses by the APA and academic psychiatrists to criticisms of psychiatric medications, or to studies revealing that leading psychiatrists have conflicts of interests. Their responses regularly tell of an endorsement for pharmacotherapy and assertions that researchers are unaffected by commercial ties, rather than a willingness to engage with the findings that question the risk benefit ratio of psychotropic medications.
For instance, in 2008, Irving Kirsch and colleagues conducted a meta-analysis of the clinical trial data submitted to the Food and Drug Administration for four antidepressants, and he grouped drug versus placebo results according to how severely ill the patients were at the beginning of the study. He found that the drugs did not provide a clinically meaningful benefit to most patients with depression. It was only in the very severely ill that the drugs provided this benefit, according to the clinical trial results.
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Two years later, Fournier came to a similar conclusion. In many clinical trials, the drug companies use a washout period (i.e., the elimination of initial placebo responders), a trial design that is expected to suppress the placebo response.
Fournier et al. conducted a meta-analysis of clinical trials that randomized patients either to placebo or drug (regardless of whether they initially responded to the placebo), and they also included information about the severity of the patients' symptoms in the trial. Fournier and colleagues were able to find only six such studies in the literature, and in those six studies, "true drug effects-an advantage of antidepressant over placebo-were nonexistent to negligible among depressed patients with mild, moderate and even severe baseline symptoms, whereas they were large for patients with very severe symptoms." In short, the response by the APA and other leading psychiatrists to criticism that challenged guild interests has been this: psychiatric drugs work quite well, better than suggested by the clinical data, and the leaders in the field are expert scientists, unaffected by their financial ties to industry. Studies of cognitive dissonance reveal is that the APA and its leaders are quite certain that that all classes of psychotropic medications are effective and safe. Furthermore, emerging evidence that suggests otherwise must be of poor quality or simply wrong.
Medical Consequences
Conflicts of interest can affect all aspects of psychiatry's medical practices. In research, it can lead researchers to make design and methodological choices that may overemphasize the effectiveness of the drugs and minimize the adverse events. In the delineation of diagnostic categories, it can lead to an expansion of the boundaries of disorders-or to the creation of new disorders-in ways that promote industry interests. Finally, it can lead the field to believe that it is practicing "evidence based medicine," with the clinical care guidelines thought to reflect the findings of honest science, when, in fact, the evidence base is "tainted" in multiple ways.
The first problem is that the published literature-which the experts rely on to develop the guidelines-may be compromised by financial conflicts of interest. If so, the guidelines will be compromised as a matter of course: bad input leads to bad output. The second problem is that the experts developing the guidelines may have a financial conflict of interest (if they have received payments from drug companies), and they will also have a "guild" interest to see the drugs in a positive light. Thus, as they review the literature, they will have a natural "confirmatory bias" to perceive study results in a manner that reflects their belief that the medications are quite helpful. Indeed, researchers have found that expert opinion on medical subjects is very unreliable and often contradicts scientific data. 33 All of the APA's guideline development group had ties to pharmaceutical companies, and a majority served on speakers bureaus (sometimes referred to as "key opinion leaders") for manufacturers of the antidepressant medications.
The concept of "evidence-based medicine" provides a medical discipline with the sense that its treatment protocols are grounded in unbiased, objective science.
However, the reality may be very different. Bias may be at work at every step of this process, from the generating of the evidence to the analysis of the literature, and that can lead to treatment guidelines that are profoundly compromised. Gupta, no solution at all. The conflict is still there, and there is research that suggests that disclosure, rather than serve as a remedy against bias, may worsen it. 35 Having "come clean," researchers may become more convinced than ever that they are not biased or influenced by such ties.
Therefore, as our society searches for solutions, it will likely need to look for ways to eliminate the conflicts of interest when research is conducted and clinical guidelines are developed. Indeed, transparency simply "shifts the problem from one of 'secrecy of bias' to 'openness of bias.'" 36 As a gold standard, financial conflicts of interest need to be prohibited, not "managed." There should be a Finally, the entire medical profession should strive to become more aware of cognitive dissonance at work within medicine, and how it can lead to biased data and imbalanced conclusions about the efficacy and safety of medications. All medical subspecialties, including psychiatry, need to understand that because conflicts of interest may lead to implicit or unconscious bias, it is necessary to try to eliminate the conflicts altogether, rather than simply disclose that such conflicts exist.
